{"analyses":[{"ciLowerLimit":"0.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.78","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.32"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8"},{"groupId":"OG001","value":"95.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2884"},{"groupId":"OG001","value":"2877"}],"units":"Participants"}],"description":"Compare overall survival (OS). Overall survival is defined as the time period between randomization and death. Surviving patients classified as lost-to-follow up or having withdrawn consent to be followed will be censored at their date of last contact or withdrawal of consent to be followed, whichever occurs first.","groups":[{"description":"Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG000","title":"Palbociclib Plus Endocrine Therapy (Arm A)"},{"description":"Standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG001","title":"Endocrine Therapy Alone (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}